PACIFIC EDGE LIMITED — Board/Management Information 2021

Mar 9, 2021

==> picture [235 x 58] intentionally omitted <==

PACIFIC EDGE APPOINTS ANNA STOVE AS INDEPENDENT DIRECTOR

9 March 2021: Cancer diagnostics company, Pacific Edge Limited (NZX: PEB) is pleased to welcome Anna Stove as an independent Director, effective from 15 March 2021.

Anna has global executive experience and a successful 25+ year track record in leading and driving transformational change within the healthcare sector. She has held a number of governance roles with private and listed organisations and is currently Chair of Global Women New Zealand and a director of Rua Bioscience and TAB NZ. Anna was the General Manager of GlaxoSmithKline New Zealand for seven years and prior to that, held a number of senior roles with multinational science-led healthcare companies across Europe and Asia.

Anna said: “I am excited to be joining the Pacific Edge Board. I’ve been impressed with Pacifc Edge’s patient centric approach for their Cxbladder tests, which is positively disrupting the urology landscape globally. I’m looking forward to working with Chris and the team to accelerate the company’s global growth.”

Chair of Pacific Edge, Chris Gallaher, commented: “We are delighted to welcome Anna to the Board. Her extensive international experience in the science and healthcare sectors will be of value to Pacific Edge as we continue with our growth strategy. We are at an exciting time in Pacific Edge’s commercial journey as we build on the major commercial milestones achieved in 2020 in our primary market, the USA, including coverage from the Centres for Medicare and Medicaid and commercial agreement with Kaiser Permanente, the largest integrated healthcare provider in the US.”

Anna Stove has been appointed by the current Pacific Edge Directors, as permitted under Pacific Edge’s constitution. She will hold office until Pacific Edge’s 2021 Annual Meeting at which time she will offer herself for election by shareholders. The Board has determined that Anna will be an independent Director.

ENDS

For more information contact:

David Darling Chief Executive Officer Pacific Edge Ltd P: +64 (3) 479 5800

OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com

Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and commercialisation of diagnostic and prognostic tests for better detection and management of cancer. Its Cxbladder suite of non-invasive, simple to use and accurate diagnostic tests provide actionable results, and better detection and management of urothelial cancer. The company is developing and commercialising its range of Cxbladder bladder cancer tests globally through its wholly owned central laboratories in New Zealand and the USA. The company’s products have been tested and validated in international multi-centre clinical studies.

==> picture [235 x 58] intentionally omitted <==

ABOUT Cxbladder Triage www.cxbladder.com

Cxbladder Triage combines the power of the genomic biomarkers with additional phenotypic and clinical risk factors to accurately identify patients with haematuria who have a low probability of bladder cancer and may not require a more extensive urological evaluation. Cxbladder Triage is a tool for use by clinicians and physicians in primary evaluation of patients with haematuria and is intended to reduce the need for an expensive and invasive work-up in patients who have a low probability of having urothelial carcinoma.

ABOUT Cxbladder Detect www.cxbladder.com

Cxbladder Detect enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of a patients’ urine. Cxbladder Detect provides clinicians with a quick, cost effective and accurate measure of the presence of the cancer as an effective adjunct to cystoscopy.

ABOUT Cxbladder Monitor www.cxbladder.com

Cxbladder Monitor allows urologists to monitor bladder cancer patients for recurrence of the disease. Bladder cancer has a recurrence rate of 50-80% and requires life-long surveillance. Cxbladder Monitor accurately identifies patients with a prior history of urothelial cancer (UC) whose Cxbladder Monitor score shows that they have a low probability of recurrent urothelial carcinoma. Cxbladder Monitor is designed to be used as the preferred adjunct test to cystoscopy in the management of patients for ongoing evaluation of recurrent bladder cancer.

ABOUT Cxbladder Resolve www.cxbladder.com

Cxbladder Resolve identifies those patients who are likely to have aggressive or more advanced bladder cancer. Cxbladder Resolve, when used as part of the primary evaluation of haematuria and/or in conjunction with other Cxbladder tests (Triage, Detect), is designed to assist clinicians by accurately identifying patients with a high probability of having high grade or late stage bladder cancer, for whom alternative or expedited treatment options may be warranted, or who can be prioritised for further investigation in high throughput settings.

Refer to www.cxbladder.com for more information.